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Abstract
Medulloblastoma (MB) is a pediatric tumor of the cerebellum
divided into four groups. Group 3 is of bad prognosis and
remains poorly characterized. While the current treatment
involving surgery, radiotherapy, and chemotherapy often fails, no
alternative therapy is yet available. Few recurrent genomic
alterations that can be therapeutically targeted have been iden-
tified. Amplifications of receptors of the TGFb/Activin pathway
occur at very low frequency in Group 3 MB. However, neither
their functional relevance nor activation of the downstream
signaling pathway has been studied. We showed that this path-
way is activated in Group 3 MB with some samples showing a
very strong activation. Beside genetic alterations, we demon-
strated that an ActivinB autocrine stimulation is responsible for
pathway activation in a subset of Group 3 MB characterized by
high PMEPA1 levels. Importantly, Galunisertib, a kinase inhibitor
of the cognate receptors currently tested in clinical trials for
Glioblastoma patients, showed efficacy on orthotopically grafted
MB-PDX. Our data demonstrate that the TGFb/Activin pathway is
active in a subset of Group 3 MB and can be therapeutically
targeted.
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Introduction
Medulloblastoma (MB), a cerebellar tumor, is one of the most
common malignant brain tumors in children (Holgado et al, 2017;
Wang et al, 2018). Current therapy associates surgery, chemother-
apy, and radiotherapy. This aggressive regimen allowed an increase
in the overall survival rate up to 70–80% but induces dramatic long-
term side effects (Martin et al, 2014). In addition, the overall
survival rate of high-risk patients is far below (Holgado et al, 2017;
Wang et al, 2018). It is therefore crucial to identify new treatments
that decrease side effects and improve efficacy.
Genomic and transcriptomic approaches allowed the stratifi-
cation of MB patients into 4 different molecular groups: WNT (Win-
gless), SHH (Sonic Hedgehog), Group 3, and Group 4 (Northcott
et al, 2012a; Taylor et al, 2012). These groups display differences in
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terms of cell of origin, transcriptional, epigenetic, and mutational
signatures. They also differ in their clinical characteristics such as
histology, overall survival rate, and presence of metastases.
Recently, intragroup heterogeneity has been further uncovered,
allowing their division into subtypes with some specific clinical
parameters as well as genomic alterations (Cavalli et al, 2017a;
Northcott et al, 2017; Schwalbe et al, 2017). Although the existence
of subdivisions within the different groups is clear, the outlines of
the different subtypes have not completely reached a consensus so
far. The WNT group represents 10% of all MBs and is driven by
constitutive activation of the WNT/b-catenin pathway with patients
showing the best prognosis. The SHH group accounts for 20–25% of
MB and is characterized by mutations involving different mediators
of the SHH pathway. It is considered of intermediate prognosis.
However, recent sub-classifications identified SHH subtypes with
poorer outcomes (Cavalli et al, 2017a; Schwalbe et al, 2017). On the
other side, Group 3 and Group 4 are far less characterized due to
their genetic and clinical heterogeneity. They display some degrees
of overlap with a few samples (~10%) being difficult to specifically
assign to either Group. They share some clinical characteristics,
such as a high propensity to metastasis and genetic alterations such
as OTX2 amplifications or KBTBD4 mutations (Northcott et al,
2017). In contrast to SHH and WNT groups, no deregulation of a
given signaling pathway has been yet reported. Group 4 represents
35–40% of all MB patients and shows, in few cases, MYCN and
CDK6 amplifications and KDM6A mutations. Recently, it has been
shown that genomic alterations involving enhancer hijacking induce
PRDM6 overexpression in 15–20% of Group 4 (Northcott et al,
2017). Group 3 represents 20–25% of MB patients and is associated
with bad prognosis. This group is highly metastatic and character-
ized by MYC overexpression, which can be explained in 15–20% of
cases by its amplification. However, MYC overexpression is not suf-
ficient to induce Group 3 MB and requires additional cooperating
oncogenic events (Kawauchi et al, 2012; Pei et al, 2012). Some of
them have been identified, such as GFI1 and GFI1B that are highly
expressed in a subset of Group 3 through enhancer hijacking
(Northcott et al, 2014). These transcription factors have been
demonstrated to drive Group 3 MB tumorigenesis in animal models
when associated with MYC overexpression (Northcott et al, 2014).
At the transcriptomic level, Group 3 is characterized by the expres-
sion of a photoreceptor program defined by genes whose expression
is highly restricted to the retina (Kool et al, 2008; Cho et al, 2011).
We recently uncovered that this program defines a subtype within
Group 3 tumors, which exhibits a functional dependency to this
ectopic program through its two main drivers, the retina-specific
transcription factors NRL and CRX (Garancher et al, 2018). Thus,
Group 3 can be subdivided into 2–3 different subtypes according to
the different studies (Cavalli et al, 2017a; Northcott et al, 2017;
Schwalbe et al, 2017). Cavalli et al (2017a) have identified 3
subtypes, one is composed of tumors with high MYC expression
including those with amplification of this gene, named G3c. This
subtype has the worse prognosis. The second subtype, G3b, is over-
represented by tumors with GFI1 alterations, and the last one G3a,
by tumors expressing photoreceptor genes in which few amplifi-
cations of mediators of the TGFb/Activin pathway can be found
(Cavalli et al, 2017a). Since Group 3 displays the worse prognosis,
targeted therapies are actively searched. Different actionable targets
have been proposed mainly based on genomic data, including the
TGFb signaling, which has been suggested to be deregulated in few
Group 3 MB, although no functional data have been reported so far.
A study on structural genomic variations across over 1,000 MB has
first described few amplifications of different mediators of the
TGFb/Activin pathway in Group 3 MB (Northcott et al, 2012b).
They include ACVR2A and ACVR2B, two type II receptors for
Activin, as well as TGFBR1, a type I receptor for TGFb, highlighting
a potential deregulation of Smad2/3 signaling (see below). Addition-
ally, since OTX2 has been demonstrated to be a target gene of this
signaling pathway (Jia et al, 2009), it has been proposed that OTX2
amplifications could represent a mechanism by which the pathway
is also deregulated downstream (Northcott et al, 2012b). The puta-
tive significance of this signaling pathway in Group 3 was reinforced
by two subsequent studies, one involving sequencing in a large
cohort of MB (Northcott et al, 2017) and the other showing that
several components of this signaling pathway could also be deregu-
lated at their expression level, through Group 3-specific enhancers
(Lin et al, 2016). Although these studies might indicate a potential
deregulation of the Smad2/3 signaling pathway, this could account
for only a modest proportion of Group 3 tumors.
The TGFb superfamily is a large family of cytokines divided into
two distinct groups of ligands: the TGFbs/Activins and the BMPs.
TGFb/Activin ligands signal through Smad2/3. These ligands bring
together two types of serine/threonine kinase receptors, the type I
and the type II, which are specific for a set of ligands. The TGFbs
(TGFb1, TGFb2, and TGFb3) signal through the TGFBR1 type I and
TGFBR2 type II receptors. Activin, encoded by 4 different genes,
INHBA, INHBB, INHBC, and INHBE, can activate different couples of
receptors including the ACVR2A and ACVR2B type II and ACVR1A
(ALK4) and ACVR1C (ALK7) type I receptors. INHA, encoding
inhibin-a, is an inhibitor of the Activin ligands. Activin and TGFb
ligands lead to the phosphorylation and activation of the same intra-
cellular mediators, Smad2 and Smad3, which then associate with
the co-Smad, Smad4. The hetero-complex translocates to the
nucleus, where it activates the transcription of target genes with the
help of DNA binding partners (Levy & Hill, 2006; Ross & Hill, 2008).
TGFb/Activin signaling displays pleiotropic functions depending
on the cellular and environmental context. Its implication in cancer
has been well documented, mainly through TGFb ligands, although
BMPs and Activins ligands can be also involved (Seoane & Gomis,
2017). The role of the TGFb signaling pathway in cancer is complex,
acting either as a tumor suppressor pathway in some instances or as
a tumor promoter in others (Massague´, 2008; Seoane & Gomis,
2017). Its oncogenic role is mainly associated with an autocrine (or
paracrine) stimulation, due to the strong expression of TGFb
ligands. The TGFb pathway has been shown to promote cell prolif-
eration in specific context such as in Glioblastoma (Bruna et al,
2007) and cancer stem cell maintenance (Pen˜uelas et al, 2009;
Anido et al, 2010; Lonardo et al, 2011). Studies on the role of
Activin ligands in cancer are much more scarce (Wakefield & Hill,
2013). By activating the same mediators Smad2/3, a parallel can be
drawn between TGFb and Activin. Indeed, Activins act both as
tumor suppressors and tumor promoters (Chen et al, 2002; Antsifer-
ova & Werner, 2012; Marino et al, 2013; Wakefield & Hill, 2013).
Their pro-tumorigenic role has been validated in animal models in
which deletion of the activin inhibitor, INHA, led to gonadal tumors
in mice as well as cachexia-like syndrome (Matzuk et al, 1994;
Vassalli et al, 1994). ActivinB has also been shown to play a role in
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cancer stem cell maintenance (Lonardo et al, 2011) and in cell
dedifferentiation in an insulinoma mouse model and deletion of
INHBB encoding ActivinB increases survival (Ripoche et al, 2015).
Several observations pinpoint to a potential role of the Smad2/3
signaling pathway in Group 3 MB but no published data have con-
firmed the deregulation of this signaling pathway, nor its functional
involvement in Group 3 biology. In this study, we investigated these
aspects to bring the proof of principle that this signaling pathway
represents an interesting therapeutic target in MB and to identify
patients that could be eligible to such therapy.
Results
TGFb/ActivinB signaling pathway is active in Group 3 MB
Since different genomic alterations in the TGFb/Activin pathway
have been previously described in Group 3 MB (Northcott et al,
2012b, 2017; Lin et al, 2016), we first investigated whether the path-
way is activated in patient samples. We performed WB analysis on
38 medulloblastomas: 7 WNT, 12 SHH, 10 Group 3, and 9 Group 4
tumors. Activation of the pathway, monitored by the level of Smad2
phosphorylation (P-Smad2), was observed in some patient samples
from all MB groups (Fig 1A). An inter-tumor heterogeneity was
observed in each group, with some samples with high P-Smad2.
However, an overall higher level of Smad2 phosphorylation was
observed in Group 3 when normalized to b-actin (Fig EV1A, left
panel). This was not evidenced when normalized to total Smad2
(Fig EV1A, right panel) since an important variation of Smad2 level
was observed (Fig 1A). This is in line with the modification of
Smad2 stability by auto-regulatory mechanisms (Yan et al, 2018).
Thus, the overall level of P-Smad2/b-actin, which formally reflects
the level of nuclear and active Smad2, led us to conclude that
TGFb/Activin pathway is activated in some Group 3 patients.
Considering that amplifications of receptors of the pathway have
been described in less than 10% of Group 3 tumors (Northcott et al,
2012b), we hypothesized that other mechanisms may account for
pathway activation in several G3 samples. Activation of the Smad2/
3 pathway in cancer is frequently due to autocrine/paracrine activa-
tion by TGFb ligands (Rodo´n et al, 2014). Therefore, we analyzed
the expression of major mediators of the TGFb/Activin pathway,
including ligands and receptors in previously published MB dataset
at the mRNA (Data ref: Cavalli et al, 2017b) and protein (Data ref:
Archer et al, 2018b) levels. No major difference in the expression of
the different receptors was observed between the different groups
(Fig EV1B and C). In contrast, striking differences were observed
for the ligands. For example, TGFB2 was found highly expressed in
SHH tumors (Fig EV1B and C and Appendix Table S1). We observed
higher expression levels of TGFB1, TGFB3, and INHBB (encoding
ActivinB) in Group 3 in comparison with the other ones although
expression of TGFB3 is similar between Group 3 and Group 4
(Fig 1B). These results were confirmed at the protein level
(Fig EV1C). These data were compatible with an autocrine activa-
tion of the pathway by one of those ligands listed above in Group 3
MB.
We next investigated the activation of TGFb/Activin pathway in
MB cell lines. We analyzed the level of P-Smad2 in four well-estab-
lished Group 3 MB cell lines (HDMB03, D458, 1603MED, and D283)
as well as in three cell lines classified as non-Group 3 (DAOY,
ONS76, and UW228). Western Blot (WB) analyses showed higher
basal intensity of P-Smad2 signal in Group 3 cell lines (Fig 1C), con-
firming that the pathway is activated in this group. As in patient
samples, we observed heterogeneity in the activation of the path-
way, with a very strong basal level of pathway activation being
observed in the 1603MED cell line while in some cell lines its level
was modest.
To understand what drives the basal activation of the pathway in
Group 3 cell lines, we investigated the expression level of different
ligands and receptors of the pathway by RT–qPCR (Figs 1D and
EV1D). No marked difference in the expression of the receptors was
found between Group 3 and non-Group 3 cell lines, except a higher
expression of ACVR1B, ACVR2A, and ACVR2B (Fig EV1D and
Appendix Table S2) and a lower expression of TGFBR2, an obliga-
tory partner for TGFBR1, in Group 3 cell lines. We did not observe
any direct correspondence between the expression of the different
receptors and the level of activation of the pathway in the different
Group 3 cell lines (i.e., level of P-Smad2 in Fig 1C), suggesting that
pathway activation is not directly linked to the deregulation of
receptors expression. We investigated the expression of different
ligands (Figs 1D and EV1D) and found a higher expression of INHBB
in the 1603MED and D283 Group 3 cell lines as compared to the
others (Fig 1D and Appendix Table S2). Interestingly, this level of
expression directly corresponded to that of P-Smad2 levels, strong
in 1603MED to intermediate in D283. This suggested that the Acti-
vinB, encoded by INHBB, could be the major driver of Smad2/
Smad3 phosphorylation in this group. The same observation could
be drawn for TGFB3 in 1603MED and to a lesser extent in D283,
while genes encoding the other ligands were not overexpressed in
the cell lines showing a high level of P-Smad2 (Fig EV1D). Taken
together, these results suggested the potential existence of an auto-
crine mechanism involving either TGFB3 or INHBB that could be
responsible for TGFb/Activin signaling activation in Group 3 MB.
An autocrine stimulation involving ActivinB
To further investigate the presence of a potential autocrine mecha-
nism, we first analyzed the ability of cell lines to respond to exoge-
nous stimulation by either TGFb or Activin ligands, each requiring
different sets of receptors. Non-Group 3 cell lines showed an
increase in P-Smad2 signals in response to TGFb stimulation, while
no modulation was observed upon Activin stimulation (Fig 2A, left
in blue). Strikingly, Group 3 MB cell lines showed the complete
opposite profile: P-Smad2 signal was increased upon Activin stimu-
lation, while it remained unchanged upon TGFb stimulation
(Fig 2A, right in yellow). Noteworthily, 1603MED displayed a very
high basal level of P-Smad2 which is constitutive. The reason for
which G3 cell lines respond to Activin but not to TGFb is currently
unknown. However, we noticed a lower level of TGFBR2 in these
cells, a receptor required for TGFb response (Fig EV1D). This was
also observed in G3 tumor samples at the RNA and protein level
(Fig EV1B and C). These opposite responses suggested a ligand-
specific response between MB subgroups with Group 3 MB cell lines
being able to respond to Activin but not to TGFb, thereby excluding
TGFb ligands as a potential autocrine source for Smad2 activation.
Since Group 3 cell lines displayed concomitant pathway activation
and INHBB expression, these results strongly suggested that an
ª 2019 The Authors EMBO Molecular Medicine e9830 | 2019 3 of 17
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Figure 1. TGFb/ActivinB pathway is activated in Group 3 MB patients and cell lines.
A Immunoblot analysis of phosphorylated Smad2 (P-Smad2) and PMEPA1 (high and low exposures displayed) in MB patient sample lysates from different groups: WNT
(blue), SHH (red), Group 3 (yellow), or Group 4 (green). b-Actin was used as a loading control. Relative quantification of P-Smad2 signal to b-actin (P-S2/b-Actin) and
total Smad2 (P-S2/Tot-S2) are indicated below the blots.
B Boxplots summarizing the expression of INHBB, TGFB1, and TGFB3 ligands of the TGFb/Activin pathway in the different groups of MB (blue WNT, red SHH, yellow
Group 3, and green Group 4) and in fetal and adult cerebellum (gray) in the dataset of Cavalli et al (Data ref: Cavalli et al, 2017b).
C Immunoblot analysis of phosphorylated Smad2 (P-Smad2) in non-Group 3 (blue) and Group 3 (yellow) MB cell lines on the left panel. The level of total Smad2
(Smad2) was assessed, and b-actin was used as a loading control. On the right panel, relative level of P-Smad2 (P-S2) was quantified to total b-actin. P-Smad2 to
total Smad normalization is also provided on Appendix Fig S5.
D RT–qPCR was performed on RNA extracted from non-Group 3 (blue) and Group 3 (yellow) MB cell lines to compare expression levels of INHBB (left) and TGFB3 (right).
Data information: Wilcoxon rank-sum tests were performed to determine P-values for panel (B). Boxplot center lines show data median; box limits indicate the 25th and
75th percentiles; lower and upper whiskers extend 1.5 times the interquartile range (IQR) from the 25th and 75th percentiles, respectively. Outliers are represented by
individual points (B). The remaining P-values were determined by unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Bars represent the mean  SD.
Number of replicates is n ≥ 3. The exact P-values and number of replicates are indicated in Appendix Table S5. Detailed statistics are presented in Appendix Table S1 for
panel (B) and Appendix Table S2 for panel (D).
Source data are available online for this figure.
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ActivinB (encoded by INHBB) autocrine stimulation could be
responsible for the activation of the pathway in the 1603MED and
D283 Group 3 cell lines. To further investigate the potential role of
ActivinB in the basal Smad2 activation in these cell lines, we
focused on the 1603MED cell line, which shows the strongest basal
activation. Treatment of 1603MED cells with an ActivinB blocking
antibody induced a decrease in P-Smad2 level (Fig 2B). Importantly,
the specificity of this antibody toward ActivinB was verified by
showing that it does not block TGFb stimulation (Appendix Fig S1).
These experiments supported that an autocrine ActivinB production
induced, at least partially, a strong activation of the pathway in
1603MED. This was further supported by P-Smad2 inhibition upon
treatment with follistatin, a ligand trap for Activins (Fig 2B). We
next sought to directly demonstrate that 1603MED cells secrete Acti-
vinB. HDMB03 cells were used as receiving cells to conditioned
media, since they showed the lowest basal activation of the pathway
among G3 cell lines (Fig 1C) but efficiently responded to exogenous
ActivinB and not to TGFb stimulation (Fig 2A). Three culture media
were tested as follows: a non-conditioned media that had never
been in contact with any cells, an HDMB03-conditioned media, both
of them being used as negative controls, and a 1603MED condi-
tioned media. HDMB03 cells were treated with these different media
for 1 h, and the effect on the Smad2 pathway was tested by WB
(Fig 2C). 1603MED conditioned media induced a strong P-Smad2
signal as compared to the two control media. This induction was
prevented by incubation with an ActivinB blocking antibody
(Fig 2C), strongly supporting that 1603MED secreted active ActivinB
ligand. To further substantiate this hypothesis, we targeted INHBB
expression by siRNA in 1603MED. Although expression of INHBB
was reduced to only 40% (Fig 2D), we nonetheless observed a
decrease in P-Smad2 level (Fig 2E) resulting in decreased cell
growth (Fig 2F). All these effects were rescued by exogenous addi-
tion of ActivinB (Fig EV2). Altogether, these results strongly support
an autocrine secretion of ActivinB by 1603MED cells leading to
P-Smad2 activation and promoting 1603MED cell proliferation.
ActivinB stimulation promotes proliferation
We next investigated the role of Activin pathway activation in
Group 3 MB cell lines. D458 (Fig 3A–D) and D283 (Fig 3E–H) cells,
which showed intermediate basal activation of the pathway
(Fig 1C), were stimulated with ActivinB (Fig 3). Activation of the
pathway was validated by monitoring P-Smad2 levels (Fig 3A and
E). Incucyte Proliferation Assay revealed an increase in cell prolifer-
ation upon ActivinB stimulation in both cell lines (Fig 3B and F). It
remains to be determined why ActivinB did not promote cell growth
while activating the pathway in HDMB03 (Appendix Fig S2). An
increase in cell proliferation can result from faster cell cycle progres-
sion, a reduction in cell death, or both. We analyzed the cell cycle
profile by BrdU incorporation and 7AAD labeling and observed an
increase in the number of cells in S phase following ActivinB stimu-
lation, concomitant with a decrease in G0/G1 (Fig 3C and G). Apop-
tosis was monitored by FACS analysis of cleaved caspase-3 staining.
We did not detect consistent effects on apoptosis, with a slight
decrease in D458 cell line following stimulation after 2 days
(Fig 3D), while no changes were detected in D283 (Fig 3H). These
results indicated that ActivinB stimulates cell proliferation in Group
3 cell lines mainly by promoting cell cycle progression.
Inhibition of the pathway decreases proliferation
We next investigated the consequences of pharmacological inhibition
of the pathway in Group 3 MB cell lines (Fig 4). One Group 3 cell line
that exhibits a very high basal activation of the pathway (1603MED,
Fig 4A–D) and one with an intermediate level (D283, Fig 4E–H) were
treated with LY364947 or SB431542. These compounds prevent the
phosphorylation of Smad2/3 by the TGFb and Activin type I recep-
tors. Indeed, we verified that they prevent TGFb- as well as ActivinB-
induced P-Smad2 (Appendix Fig S1). After 24 h of treatment, the
level of P-Smad2 was decreased in 1603MED and D283 cell lines
(Fig 4A and E, respectively). This pathway inactivation was accom-
panied by a decrease in cell proliferation (Fig 4B and F). FACS analy-
ses were performed to measure BrdU incorporation and 7AAD
labeling. Treatment with inhibitors induced a decrease in the
percentage of cells in S phase concomitant with an increase in G0/G1
(Fig 4C and G). A very slight increase in the percentage of cells posi-
tive for cleaved caspase-3 staining was also observed (Fig 4D and
H), showing that the inhibition of the pathway mainly impacted on
cell cycle and to a much lesser extent on apoptosis.
PMEPA1 is implicated in ActivinB promotion of cell growth
To identify relevant genes downstream of Activin signaling in Group
3 MB, we sorted the top 10 genes, whose expression was correlated
with INHBB in Group 3 patient samples (Fig 5A). PMEPA1, which
scored as the top gene, is a well-established Smad2/3 target gene in
different cell types including P19 cells stimulated by Activin (Coda
et al, 2017). Accordingly, we found that PMEPA1 expression level
was enriched in Group 3 MB (Fig 5B) and correlated with INHBB
expression in MB (Fig 5C). This correlation is highest in G3 as
compared to the other groups (Appendix Fig S3A). Accordingly, we
observed a good correspondence between P-Smad2 overall level and
PMEPA1 protein expression in patient samples by Western blot anal-
ysis (Figs 1A and 5D and E, Appendix Fig S3B). We next tested
whether PMEPA1 is also a target of the Smad2 signaling in MB by
modulating pathway activation (Fig 5F). Activation of the pathway
by ActivinB induced an increase in PMEPA1 mRNA and protein
levels, while its inhibition by LY364947, SB431542, blocking Acti-
vinB antibody, or follistatin had the opposite effect in G3 cell lines
(Fig 5F and Appendix Fig S3C and D). MYC and OTX2 are key play-
ers in Group 3 MB and are also known as Smad2/3 target genes in
other cell types (Jia et al, 2009; Brown et al, 2011; Coda et al, 2017).
Therefore, we investigated whether their expression could be modu-
lated by this pathway in Group 3 MB cell lines. In contrast to
PMEPA1, no major change was observed at the mRNA (Appendix Fig
S3C) and protein (Fig 5F and Appendix Fig S3D) levels upon path-
way inhibition regarding OTX2, while a slight decrease could be
observed for MYC. However, no significant increase in MYC expres-
sion was observed upon ActivinB treatment (Appendix Fig S3C).
Interestingly siRNA-mediated INHBB knockdown decreased PMEPA1
expression that could be rescued upon ActivinB treatment
(Fig EV3A). These results suggested that PMEPA1 is a target gene of
the Activin pathway in Group 3 MB but that neither MYC nor OTX2,
two important players of this group, appears to be consistently regu-
lated by this signaling pathway although minor effects are observed
on MYC. The role of PMEPA1 in cancer remains unclear and is likely
to be cell type specific. It has been shown to either promote or
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restrain cancer progression (Liu et al, 2011; Fournier et al, 2015;
Nie et al, 2016). Therefore, we investigated its role in Group 3 MB.
siRNA-mediated PMEPA1 knockdown resulted in cell growth inhibi-
tion in both 1603MED and D283 cell lines (Figs 5G–J and EV3B–E),
suggesting that PMEPA1 is an important mediator of Activin signal-
ing-mediated proliferation in Group 3 MB.
TGFb/ActivinB signaling pathway in Group 3 MB Patient Derived
Xenografts (PDXs)
We further validated the importance of the pathway in patient
derived xenograft (PDX) models, known to remain close to the origi-
nal tumor (Fig 6). As observed in Group 3 patient samples and cell
A
C D E F
B
Figure 2. An autocrine stimulation by ActivinB in the 1603MED cell line.
A–C The level of phosphorylated Smad2 (P-Smad2) and total Smad2 (Smad2) was assessed by immunoblotting, and b-actin was used as a loading control. Lower bar
graphs show WB quantification of P-Smad2 (P-S2) normalized to b-actin. (A) Activation of the pathway was assessed in non-Group 3 (blue) and Group 3 (yellow)
MB cell lines in response to TGFb or ActivinB stimulation for 1 h. (B) 1603MED cells were treated with PBS (vehicle) or a blocking antibody targeting ActivinB (Ab a-
ActB) or follistatin. (C) Conditioned media experiments were performed on the HDMB03 MB cell line. Phosphorylation of Smad2 was analyzed by immunoblot upon
treatment with either non-conditioned media (NCM), media conditioned with HDMB03 cells (CM-HDMB03), or media conditioned with 1603MED cells (CM-1603).
Pre-incubation with blocking antibody against ActivinB (Ab a-ActB) or vehicle (PBS) was performed before HDMB03 cell-line treatment as indicated. Relative level
of P-Smad2 (P-S2) was quantified to b-actin (below).
D RT–qPCR was performed on total RNA extracted from 1603MED cells 48 h after transfection with siRNA targeting INHBB. Relative INHBB expression was assessed.
siCTRL condition was set at 1.
E 1603MED cells were transfected with the indicated control siRNA (siCTRL, blue) or targeting INHBB (siINHBB, red). Lysates were prepared 48 h after transfection.
The level of phosphorylated Smad2 (P-Smad2) and total Smad2 (Smad2) was assessed by immunoblotting, and b-actin was used as a loading control. Lower bar
graphs represent the quantification of the relative level of P-Smad2 (P-S2) to b-actin.
F Growth curve of 1603MED cells after transfection with either siCTRL (blue) or siINHBB (red).
Data information: P-Smad2 to total Smad normalization is provided on Appendix Fig S5. The P-values were determined by unpaired t-test. *P < 0.05, **P < 0.01,
***P < 0.001. Bars represent the mean  SD. Number of replicates is n ≥ 3. The exact P-values and number of replicates are indicated in Appendix Table S5.
Source data are available online for this figure.
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lines, we found heterogeneous levels of P-Smad2, from high to
moderate, in the three Group 3 PDXs tested (Fig 6A). PDX4
displayed a very strong activation of the pathway, similar to that
observed in the 1603MED cell line. We investigated the expression
level of different mediators of the pathway by RT–qPCR (Fig 6B,
Appendix Fig S4A). This analysis showed heterogeneous expression
levels of INHBB in the 3 PDXs (Fig 6B), which tightly corresponded
to the level of P-Smad2. PDX4, which showed the highest level of
expression of INHBB, also displayed the highest P-Smad2 signal (see
level of P-Smad2 in Fig 6A and INHBB expression in 6B). As in cell
lines, Group 3 PDXs responded to Activin but not to TGFb stimula-
tion (Fig 6C). This result supported the observations in MB cell
lines, suggesting a ligand specificity toward Activin in Group 3 MB.
To further investigate the possibility of an autocrine mechanism
involving ActivinB, we performed conditioned media experiments
as described in Fig 2C. Conditioned media from PDX4, which
displays a strong activation of the pathway, markedly increased P-
Smad2 phosphorylation in the receiving HDMB03 cells (Fig 6D).
This induction could be partially prevented when the media was
pre-incubated with an ActivinB blocking antibody (Fig 6D). More-
over, PDX4 treated with the same antibody also showed a decrease
in P-Smad2 (Fig 6E, Appendix Fig S4C). P-Smad2 signal could also
be inhibited following treatment with inhibitors of type I receptors
and follistatin (Fig 6E). We next assessed if this signaling pathway
controls PMEPA1 expression. As in cell lines, a decrease in PMEPA1
expression was observed in PDXs after treatment with inhibitors
and increased by ActivinB treatment. The expression of MYC and
OTX2 remained mostly unchanged (Fig 6E, Appendix Fig S4B and
C). Altogether, these results confirmed those obtained in cell lines,
highlighting the presence of an autocrine stimulation involving Acti-
vinB in Group 3 MB and identified PMEPA1 as a gene, whose
expression is controlled by this signaling pathway. We next investi-
gated if inhibition of this pathway could be of therapeutic interest
in vivo. The human PDX4, which displays a very high level of acti-
vation of the pathway, was orthotopically grafted into the cerebel-
lum of nude mice. Animals were then treated 7 days per week twice
a day with Galunisertib, a pharmacological inhibitor currently in
clinical trial for Glioblastoma, Cisplatin as described in Niklison-
Chirou et al (2017), or a combination. Galunisertib is described as a
TGFb type I inhibitor but, since TGFb and Activin type I receptors
are very similar, it also inhibits very efficiently ActivinB-induced
Smad2 activation (Appendix Fig S1). Accordingly, we verified that
Galunisertib recapitulated the main in vitro data obtained with
LY364947 and SB431542 (Fig EV4A–C). Galunisertib-treated mice
survived longer as compared to controls (Fig 7A), demonstrating
the benefit of such treatment in tumors displaying high level of acti-
vation of the pathway. Accordingly, Galunisertib-treated mice
displayed smaller tumors with less P-Smad2 (Fig 7B and C). No
major difference was observed for Ki67 and cleaved caspase-3 stain-
ing (Fig EV4D and E). Although we did not observe any benefit
from the combination of Galunisertib with Cisplatin (Figs 7A–C and
EV4D and E), we cannot not exclude that different treatment kinet-
ics could be more efficient. In this respect, other combinations with
different drugs or radiotherapy remain to be evaluated.
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Figure 3. ActivinB promotes cell proliferation in Group 3 MB cell lines.
A–H D458 (A–D) or D283 (E–H) cell lines were treated with PBS (vehicle, black) or with ActivinB (green). (A and E) Immunoblot of phosphorylated Smad2 (P-Smad2), total
Smad2, and b-actin in response to ActivinB stimulation for 24 h. Quantification of P-Smad2 (P-S2) to b-actin is shown on right panels. (B and F) P-Smad2 to total
Smad normalization is provided on Appendix Fig S5. Growth curve experiments showing cell proliferation upon ActivinB treatment. (C and G) Cell cycle analysis by
FACS measuring BrdU incorporation and 7AAD labeling at 48 h upon ActivinB stimulation. The percentage of cells in the different phases of the cell cycle is
represented (G0/G1, S, and G2/M phases). (D and H) Percentage of apoptotic cells measured by FACS analysis of cleaved caspase-3 48 h after treatment with
ActivinB. The P-values were determined by unpaired t-test and two-way ANOVA for (B and F). *P < 0.05, **P < 0.01, ***P < 0.001. Bars represent the mean  SD.
Number of replicates is n ≥ 3. The exact P-values and number of replicates are indicated in Appendix Table S5.
Source data are available online for this figure.
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TGFb/ActivinB signaling pathway in Group 3a subtype of MB
As mentioned above, tumor samples, PDXs, and cell lines from Group
3 displayed an inter-tumoral heterogeneity regarding the level of
pathway activation, some of them showing a very strong P-Smad2
basal level. Recently, intragroup heterogeneity has been described in
MB (Cavalli et al, 2017a; Northcott et al, 2017; Schwalbe et al, 2017)
with the definition of new subtypes within Group 3 tumors. We
A B C D
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Figure 4. TGFb/ActivinB signaling promotes cell proliferation in Group 3 MB cell lines.
A–H 1603MED (A-D) or D283 (E-H) cells were treated with DMSO (vehicle, black), with LY364947 (red), or with SB431542 (orange). (A and E) Immunoblot of
phosphorylated Smad2 (P-Smad2), total Smad2, and b-actin upon inhibition of TGFb/Activin signaling using LY364947 and SB431542 inhibitors for 24 h. Bar graphs
on the right panel represent the quantification of the relative level of P-Smad2 (P-S2) to b-actin. (B and F) P-Smad2 to total Smad normalization is provided on
Appendix Fig S5. Growth curve experiments showing cell proliferation upon TGFb/Activin signaling inhibition. (C and G) Cell cycle analysis by FACS measuring BrdU
incorporation and 7AAD labeling at 48 h upon inhibition. The percentage of cells in the different phases of the cell cycle is represented (G0/G1, S, and G2/M
phases). (D and H) Percentage of apoptotic cells measured by FACS analysis of cleaved caspase-3 48 h after TGFb/Activin signaling inhibition. The P-values were
determined by unpaired t-test and two-way ANOVA for (B and F). *P < 0.05, **P < 0.01, ***P < 0.001. Bars represent the mean  SD. Number of replicates is
n ≥ 3. The exact P-values and number of replicates are indicated in Appendix Table S5.
Source data are available online for this figure.
▸Figure 5. PMEPA1 is a target gene involved in the response to Activin signaling.A Ranking of top genes whose expression is correlated with INHBB in Group 3 MB patient samples. Spearman’s rank correlation coefficient q and P-value are indicated.
B Boxplots representing PMEPA1 expression levels in the different MB groups (WNT in blue, SHH in red, Group 3 in yellow, and Group 4 in green) and in fetal and adult
cerebellum (gray) in the dataset of Cavalli et al (Data ref: Cavalli et al, 2017b). Only P-values corresponding to comparisons between Group 3 and the other groups
are indicated. Full statistics can be found in Appendix Table S1.
C Scatter plot of INHBB and PMEPA1 gene expression levels in all MB groups. Colored dots represent each patient samples, and colors represent the MB groups (WNT in
blue, SHH in red, Group 3 in yellow, and Group 4 in green).
D Boxplot represents the quantification of PMEPA1 protein level normalized to b-actin levels across groups.
E Scatter plot represents log2 relative protein level of P-Smad2 (x-axis) and PMEPA1 (Y-axis) normalized to b-actin in each individual samples.
F Immunoblots of phosphorylated Smad2 (P-Smad2), total Smad2, MYC, PMEPA1, OTX2, and b-actin were performed on extracts from 1603MED or D283 or D458 cells
treated with either DMSO (vehicle), LY364947, SB431542, blocking antibody against ActivinB (Ab a-ActB), follistatin, PBS, or ActivinB (ActB) for 24 h. Blot quantification
to b-actin is presented in Appendix Fig S3D.
G Immunoblot analysis of PMEPA1 levels in 1603MED cells 48 h after transfection with either siCTRL (blue) or siPMEPA1 (red). Bar graphs on the right represent the
quantification of the relative level of PMEPA1 protein level normalized to b-actin. P-Smad2 to total Smad normalization is provided on Appendix Fig S5.
H Growth curves of 1603MED cells after transfection with either siCTRL (blue) or siPMEPA1 (red).
I Immunoblot analysis of PMEPA1 levels in D283 cells 48 h after transfection with either siCTRL (blue) or siPMEPA1 (red). Bar graphs on the right represent the
quantification of the relative level of PMEPA1 protein level normalized to b-actin. P-Smad2 to total Smad normalization is provided on Appendix Fig S5.
J Growth curves of D283 cells after transfection with either siCTRL (blue) or siPMEPA1 (red).
Data information: The color code is the same as for (B, C, and E). Boxplot center lines show data median; box limits indicate the 25th and 75th percentiles; lower and
upper whiskers extend 1.5 times the interquartile range (IQR) from the 25th and 75th percentiles, respectively (B and D). Outliers are represented by individual points (B).
The P-values were determined by Spearman rank correlation test for (A and C), by unpaired t-test for (D, G and I), by two-way ANOVA for (H and J), and by Wilcoxon
rank-sum test for panel (B and E). *P < 0.05, **P < 0.01, ***P < 0.001. Bars represent the mean  SD. Number of replicates is n ≥ 3. The exact P-values and number of
replicates are indicated in Appendix Table S5.
Source data are available online for this figure.
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wondered if this intragroup heterogeneity could explain our results.
Since we showed that this strong activationwas linked to an autocrine
mechanism involving ActivinB, we investigated INHBB expression in
these newly described subtypes of Group 3 tumors (Fig 7D). We
found that INHBB displayed a significantly higher expression level in
the Group 3a subtype as compared to Group 3b and Group 3c accord-
ing to Cavalli et al (2017a) subtyping. Interestingly, PMEPA1
displayed the same profile, and consequently, INHBB and
PMEPA1 expression was tightly correlated in Group 3 (Fig 7E). In
contrast, MYC expression showed an opposite expression pattern as
compared to INHBB (Fig 7D): Group 3c subtype, which is character-
ized by an enrichment of MYC amplifications, displayed the highest
MYC expression levels, whereas the a subtype showed the lowest
(Cavalli et al, 2017a). We recently reported that NRL and CRX control
photoreceptor genes expression and define a subset of Group 3 tumors
(Garancher et al, 2018). We found that alike INHBB, NRL is highly
A B C
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Figure 5.
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expressed in the G3a subtype (Fig 7D and Appendix Table S3).
This identifies Group 3a as the subtype that expresses high level of
INHBB and high photoreceptor genes.
Discussion
Group 3 is the most aggressive MB group with patients showing the
poorest prognosis. Several genomic alterations have been identified,
including those targeting the TGFb/Activin pathway at very low
frequency. Indeed, SCNA analyses have identified uncommon gains
and/or amplifications of genes encoding receptors of the TGFb/
Activin pathway. Activation of the cognate Smad2/3 pathway in
Group 3 tumors has never been investigated, neither its potential
biological consequences nor its potential therapeutic targeting.
Using patient samples, PDXs, and cell lines, we showed that, beside
these infrequent genomic alterations, the TGFb/Activin pathway is
also activated in a specific subtype of Group 3, through an autocrine
A B
C
E
D
Figure 6.
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mechanism involving ActivinB. This pathway is involved in MB
growth and represents an interesting therapeutic target.
ActivinB mediates Smad2/3 signaling in Group 3 MB
While activation of the TGFb/Activin pathway has been described in
SHH group, no data are currently available regarding its activation in
Group 3. A recent report showed that Prune-1 may activate the TGFb
pathway in Group 3 MB but the level of pathway activation in Group
3 was not investigated nor its functional relevance (Ferrucci et al,
2018). It has also been suggested that TGFb ligands determine the
promigratory potential of bFGF signaling in MB but this study was
performed in non-Group 3 cell lines and in atypical MB-PDX
(Santhana Kumar et al, 2018). Using patient samples, we showed
here that the TGFb/Activin pathway is activated in a subset of Group
3. We confirmed these results using PDXs as well as MB cell lines. In
many different cancers, TGFb pathway activation involves autocrine
loops, due to the high expression of genes encoding the different
TGFb ligands (Rodo´n et al, 2014). We investigated the potential
mechanism of activation of the pathway in Group 3. As in other
cancers, we observed high expression of TGFB1 and TGFB3 in Group
3 MB. In addition, we also observed very high expression of INHBB,
which encodes ActivinB, suggesting that TGFb1, TGFb3, and Acti-
vinB ligands could be potentially responsible for pathway activation.
Unexpectedly, our data clearly showed that Group 3 cells do not
respond to TGFb stimulation, while they are highly sensitive to
Activin, excluding de facto TGFb1 and TGFb3 as potential ligands
that would activate the pathway in an autocrine manner. The mecha-
nism underlying the lack of TGFb responsiveness in G3 models is
currently unknown. However, we noticed a significant decrease in
RNA and protein TGFBR2 levels in G3 samples. Since TGFBR2 is
absolutely required for signal transduction by TGFb ligands, this
observation may provide a plausible explanation to this lack of
response. In any case, our experiments based on conditioned
medium, blocking antibody, follistatin treatment, and siRNA on cell
lines clearly pointed out on ActivinB as an important determinant of
pathway activation in Group 3. Importantly, these observations were
confirmed on PDXs. According to transcriptomic data showing that
INHBB expression is found in a large number of Group 3 MB, this
autocrine mechanism is very likely the main mechanism leading to
pathway activation in this group. Additional mechanisms, such as
amplifications of receptors or Prune-1 expression (see above), could
also contribute to this activation, either by cooperating with ActivinB
or by being involved in a more restricted number of Group 3 MBs
that do not exhibit this autocrine mechanism. Interestingly, while
TGFbs and Activins activate the same Smad pathway (Smad2/3),
TGFbs autocrine mechanisms have been much more frequently
described to be implicated in cancer progression than Activins (Chen
et al, 2002; Wakefield & Hill, 2013), highlighting a singularity of
Group 3 MBs. Since Activin is involved in developmental processes
(Wu & Hill, 2009), its implication in Group 3 MB instead of TGFb
may relate to the pediatric nature of these tumors or to their cell of
origin. In support of the latter and according to brain atlas data
(http://developingmouse.brain-map.org/search/show?page_num=0
&page_size=5&no_paging=false&exact_match=true&search_term=
Inhbb&search_type=gene), INHBB displays a very cell-specific and
dynamic profile during cerebellar development.
ActivinB induces PMEPA1 expression and promotes cell
cycle progression
The TGFb/Activin pathway is highly pleiotropic and sometimes
displays antagonistic functions during carcinogenic processes. For
example, it can promote either cell cycle arrest or proliferation,
depending on the context. This opposite role has been well illus-
trated in Glioblastoma in which the epigenetic status of the cells, in
particular its DNA methylation profile, is responsible for this duality
(Bruna et al, 2007). In agreement with this pro-mitogenic activity,
we found that pathway inhibition decreased cell proliferation in
Group 3 MB, while ActivinB stimulation increased it by consistently
promoting cell cycle progression. MYC and OTX2, two genes known
to promote cell proliferation in Group 3 MB, are target genes of the
Smad2/3 pathway in other contexts (Jia et al, 2009; Brown et al,
2011; Coda et al, 2017). In general, this signaling pathway reduces
MYC expression (Warner et al, 1999; Seoane et al, 2001), although it
can be induced in human embryonic stem cells (Brown et al, 2011).
Since OTX2 has been demonstrated to be a major Smad2/3 target
gene in the nervous system (Jia et al, 2009), it has been proposed to
be a Smad2/3 inducible gene in Group 3 MB (Ferrucci et al, 2018)
and considered as part of this signaling pathway in MB (Northcott
et al, 2012b). We did not detect any consistent changes in MYC and
OTX2 expression upon modulation of the Activin pathway, suggest-
ing that this signaling pathway does not regulate these two genes
in Group 3 tumors and promotes tumor growth through other
◀ Figure 6. Activated TGFb/ActivinB signaling in group 3 MB-PDXs.A Immunoblot analysis of phosphorylated Smad2 (P-Smad2) in Group 3 MB cell lines and PDXs. The level of total Smad2 (Smad2) was assessed, and b-actin was used as
a loading control. Quantification of P-Smad2 (P-S2) to b-actin is shown on right panel.
B Expression of INHBB in Group 3 MB cell lines and PDXs relative to HDMB03 (set at 1) by RT–qPCR.
C Immunoblot of phosphorylated Smad2 (P-Smad2), total Smad2, and b-actin upon ActivinB or TGFb stimulation for 1 h. Quantification of P-Smad2 (P-S2) to b-actin is
shown below.
D Conditioned media experiments were performed on HDMB03 MB cell line. Phosphorylation of Smad2 (P-Smad2) was analyzed by immunoblot upon treatment with
either non-conditioned media (NCM), media conditioned with HDMB03 cells (CM-HDMB03), or media conditioned on PDX4 cells (CM-PDX4). Pre-incubation with
blocking antibody against ActivinB (Ab a-ActB) or with vehicle was performed before HDMB03 cell-line treatment as indicated. Quantification of P-Smad2 (P-S2) to
b-actin is shown below.
E Immunoblots of phosphorylated Smad2 (P-Smad2), total Smad2, MYC, PMEPA1, OTX2, and b-actin were performed on extracts from cell cultures of PDX4, PDX3, and
PDX7 treated with either DMSO (vehicle), LY364947, SB431542, blocking antibody against ActivinB (Ab a-ActB), follistatin, PBS, or ActivinB for 24 h. WB quantification
is depicted in Appendix Fig S4C.
Data information: P-Smad2 to total Smad normalization is provided on Appendix Fig S5. The P-values were determined by unpaired t-test. *P < 0.05. Detailed statistics
are presented in Appendix Table S2 for panel (B). Bars represent the mean  SD. Number of replicates is n ≥ 3. The exact P-values and number of replicates are
indicated in Appendix Table S5.
Source data are available online for this figure.
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mechanisms. In contrast, we showed that PMEPA1, whose expres-
sion is induced by TGFb or Activin signaling in many different
contexts (Coda et al, 2017), is also an Activin-regulated gene in
Group 3 MB. Indeed, inhibition or activation of the Activin signaling
pathway modulated PMEPA1 expression accordingly. This regulation
is likely to be relevant in patients since INHBB and PMEPA1 expres-
sion is correlated in human MB samples. PMEPA1 is the top corre-
lated gene with INHBB within Group 3 MB, showing that their
expression is strongly linked in this group. In all MB samples, the
correlation is lower than within Group 3 samples. Indeed, PMEPA1
expression is higher in Group 3 but reaches an intermediate level in
WNT and SHH groups that do not express INHBB. In WNT and SHH
groups, PMEPA1 expression is likely due to TGFb/Activin pathway
activation, as highlighted by the high level of P-Smad2 found in
patient samples in those two groups, although pathway activation is
independent on ActivinB autocrine stimulation. Thus, PMEPA1
expression likely constitutes a relevant and general readout of
Smad2/3 activation, which is due to an ActivinB autocrine stimula-
tion in Group 3 and to other mechanisms in SHH and WNT groups.
The role of PMEPA1 in cancer appears to be quite complex. It has
been shown to act as negative auto-regulatory loop by limiting
Smad2/3 activation (Watanabe et al, 2010) although this appears to
be isoform dependent (Fournier et al, 2015). Other reports suggested
that PMEPA1 could promote cell proliferation in cancer cells (Vo
Nguyen et al, 2014; Nie et al, 2016) and convert TGFb/Activin
signaling from a tumor suppressor to tumor promoting pathway
(Singha et al, 2010). Although not excluding that PMEPA1 may limit
Smad2/3 activation in Group 3 MB without abolishing it, our results
are in line with those latter reports. Indeed, siRNA-mediated
PMEPA1 downregulation decreased Group 3 cell proliferation show-
ing that it is an important mediator of ActivinB promoting Group 3
MB growth.
Targeting the TGFb/Activin pathway in Group 3 as a
therapeutic perspective
We observed an activation of the Smad2 pathway in Group 3 cell
lines, PDXs, and patient samples. However, this activation appears
to be heterogeneous. For example, some cell lines and PDXs
displayed a very high basal level of Smad2 activation, while others
a much more moderate and this held true on patient samples. Since
different Group 3 subtypes have been described recently (Cavalli
et al, 2017a; Northcott et al, 2017; Schwalbe et al, 2017), we inves-
tigated whether INHBB expression could be enriched in a given
subtype. We observed that INHBB expression is higher in subtype
Group 3a according to the classification of Cavalli et al (2017a).
This subtype is characterized by the lack of MYC amplification and,
as shown in this study, an overall moderate to low MYC expression
level. This subtype displays high photoreceptor gene expression
(Cavalli et al, 2017a), including those of the two master regulators
of this program, NRL and CRX. Accordingly, we recently showed
that their expression defines a specific subtype within Group 3
(Garancher et al, 2018). Our data may suggest that the expression of
INHBB could lead to Smad2/3 activation in this subtype. Indeed, we
found that PMEPA1, whose expression can be considered as a read-
out of Smad2/3 activation (see above), is significantly higher in
Group 3a subtype as compared to other Group 3 subtypes. More-
over, its expression is tightly correlated to that of INHBB in the
Group 3 tumors, suggesting that INHBB expression leads to produc-
tive pathway activation. In support to this, PDX4, which expresses
very high level of INHBB, also displays very strong Smad2 activa-
tion. This PDX is not MYC amplified and highly expresses the
photoreceptor genes (Garancher et al, 2018). It should be neverthe-
less mentioned that the 1603MED cell line is also characterized by
high INHBB expression and high Smad2 activation but is MYC
amplified and does not express high level of photoreceptor genes
(Raso et al, 2008). Thus, we proposed that activation of the Smad2/
3 pathway involving an Activin B autocrine stimulation is enriched
in subtype Group 3a, although not limited to this subtype. Interest-
ingly, treatment with Galunisertib, whose toxicity and efficacy is
currently tested in clinical trials for Glioblastoma patients, increased
the survival of mice orthotopically grafted with PDX4. This suggests
that Group 3a patients may be particularly sensitive to pathway
inhibition.
In conclusion, the TGFb/Activin signaling is activated through
an ActivinB autocrine mechanism in a subset of Group 3 MB
subtype. Not only this pathway is activated, but it also plays a
growth-promoting role and constitutes an important driver of thera-
peutic interest in these tumors. We propose that high levels of
INHBB, PMEPA1 expression, and Smad2 phosphorylation might
constitute biomarkers for potential Group 3 patients to be eligible to
Galunisertib treatment.
◀ Figure 7. ActivinB signaling is a potential therapeutic target for patients of group 3 MB.A Kaplan–Meier representing survival of mice treated with either vehicle (black) or Galunisertib (LY2157299, red) or Cisplatin (blue) or a combination of Galunisertib and
Cisplatin (purple) after orthotopic grafting of PDX4 cells into the cerebellum. The pink rectangle represents Galunisertib treatment duration, while the blue dotted
lines represent the 3 Cisplatin administrations.
B Boxplot of tumor area after 25 days of treatment. On the right, boxplots represent quantification of P-Smad2 staining on tumor (IHC). The code color is similar to
panel (A).
C P-Smad2 staining by IHC in 3 representative tumors per group after 25 days of treatment. The scale bars represent 500 and 100 lm on the left and right panels,
respectively.
D Boxplots representing the expression level of INHBB, PMEPA1, MYC, and NRL in the different MB subtypes, as defined in Cavalli et al (2017a). Only P-values
corresponding to comparisons between Group 3 subtypes are indicated. Detailed statistics are presented in Appendix Table S3. Patient samples are colored by
subtypes as indicated.
E Scatter plot of INHBB and PMEPA1, expression levels in Group 3 patient samples. Colored dots represent each patient sample, and colors represent the group 3 MB
subtypes (a in yellow, b in brown, and d in orange). Note that this panel is identical to that shown in Appendix Fig S3A (yellow) except for the color code.
Data information: Center lines show data median; box limits indicate the 25th and 75th percentiles; lower and upper whiskers extend 1.5 times the interquartile range
(IQR) from the 25th and 75th percentiles, respectively (B and D). Squares represents individual tumor (B). Outliers are represented by individual points (D). The P-values
were determined by log-rank (Mantel-Cox) test on panel (A) and unpaired t-test on panel (B). Wilcoxon rank-sum tests were performed for panel (D). Spearman’s rank
correlation coefficient q and P-value are indicated on panel E. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Bars represent the mean  SD. Number of
replicates is n ≥ 3. The exact P-values and number of replicates are indicated in Appendix Table S5.
ª 2019 The Authors EMBO Molecular Medicine e9830 | 2019 13 of 17
Morgane Morabito et al EMBO Molecular Medicine
Materials and Methods
Bioinformatics analyses
Normalized primary medulloblastoma gene expression data (763
samples) and samples affiliation published in Cavalli et al (2017a)
were used to generate scatter plots and gene expression boxplots
per subgroup and subtype for the genes of interest. Normalized
primary medulloblastoma protein levels data (45 samples) and
samples affiliation published in Archer et al (2018a) were used to
generate protein levels boxplots per subgroup and subtype for the
proteins of interest. Wilcoxon rank-sum tests were performed
between subgroups and subtypes. Spearman rank correlation coeffi-
cients were computed between the INHBB gene expression values
and all other genes for Group 3 samples. The gene pairs were
ranked according to the Spearman correlation values.
Patient samples
All MB samples were collected following written informed consent,
and study approval was obtained by internal review boards from
the following institutions: the Necker Hospital for Sick Children
(Paris, France) and the Hospital for Sick Children (Toronto, Canada)
(Forget et al, 2018).
Cell culture conditions and treatments
HD-MB03 (named HDMB03) obtained from Dr. Milde (Milde et al,
2012), D458MED (named D458) obtained from Dr. Bigner (He et al,
1991), UW228 (Keles et al, 1995), ONS-76, and DAOY MB cell lines
(ATCC) were cultured as described in Garancher et al (2018).
1603MED obtained from Dr. Raso (Raso et al, 2008) and D283MED
(ATCC) (named D283) cell lines were maintained in DMEM condi-
tion supplemented with 12% fetal bovine serum (GIBCO), 50 units/
ml penicillin and streptomycin (Invitrogen) and 0.1 mM non-essen-
tial amino acids and sodium pyruvate. 1603MED cell lines were also
supplemented with 2 mM L-glutamine. All cells were cultured at
37°C in a humidified atmosphere containing 5% CO2. LY363947 and
SB431532 resuspended in DMSO (selleckchem) were used at a final
concentration of 5 lM for 24 h. Stimulations with TGFB1 and Acti-
vinB were performed for 1 or 24 h at 10 ng/ml. Inhibitions with a
recombinant blocking antibody against ActivinB (R&D systems) or
recombinant follistatin (R&D systems) were performed for 24 h at 5
and 0.2 lg/ml, respectively.
Growth curves and proliferation assays
For growth curve analyses, 1603MED cells were plated at 8 × 105
cells/ml, and D283 and D458 at 2.5 × 105 cells/ml. Cell were treated
once at day 0. Number of viable cells was assessed as indicated in
each figure. For D283 and D458, proliferation was monitored using
Incucyte Proliferation Assay (Essen bioscience) by analyzing the
surface occupied by cells (% confluence).
Conditioned media experiments
Receiving cells (HDMB03) were plated at 1.5 × 105 cells/well in
6-wells plates. 1603MED and HDMB03 conditioned media were
obtained by 18 h of incubation at 1 × 106 cells/ml. Non-conditioned
media was obtained in the same conditions in absence of cells.
Media were collected, filtered, and incubated with PBS as control or
blocking antibody against ActivinB (5 lg/ml) for 2 h at 4°C with
rotation. Cells were treated with 1 ml of media for 1 h, and cell
extracts were collected for WB analysis.
Western Blotting and antibodies
Cell extracts were obtained and WB analyses performed as
described in Rocques et al (2007). Membranes were incubated at
4°C overnight with anti-Smad2 (CST, CS86F7, 1/1,000), anti-Phos-
phoSmad2 (CST, CS138D4, 1/1,000), anti-OTX2 (MerckMillipore,
#AB9566, 1/10,000), anti-MYC (CST, CSD3N8F, 1/1,000), anti-
PMEPA1 (proteintech, 1/500), and anti-b-Actin (Sigma A1978,
1/5,000). Signals were acquired with a CCD camera (G/BOX,
Syngene). All the P-Smad2/Total Smad2 normalizations for the rele-
vant blots are provided in Appendix Fig S5.
Real time RT–PCR
All experiments were performed according to the protocols
described in Garancher et al (2018). Oligonucleotides used in this
study are described in Appendix Table S4.
siRNA and transfection assays
Transfection assays were performed in either 96- or 6-well plates.
siRNA transfection was performed according to the manufacturer’s
instructions (Dharmacon). DharmaFECT 3 transfection reagent was
used at 0.15 and 4 ll/100 ll of transfection medium for D283 and
1603MED cell lines, respectively. D283 cells were plated at 5 × 105
cells/ml and siRNA were used at a final concentration of 25 nM.
1603MED cells were plated at a concentration of 1 × 106 cells/ml
with 10 lM final of siRNA. Transfection assay efficiency was
assessed using siGlo (D001630-01-05). siRNA smartpool CTRL (D-
001810-00-1005), smartpool INHBB (L-011702-00-0010), smartpool
PMEPA1 (L-010501-00-0020), ON-TARGETplus individual siRNA
PMEPA1#1 (L-010501-05), and PMEPA1#2 (L-010501-08) were
purchased from Dharmacon. For rescue experiments, cells were
stimulated 10 h after transfection with ActivinB at 10 ng/ml.
Apoptosis and cell cycle analyses by flow cytometry
1603MED and D283 cell lines were plated at 8 × 105 and 2.5 × 105
cell/ml, respectively. Apoptosis was assessed at day 2 using cleaved
caspase-3 staining with Apoptosis Kit, APC (BD Bioscience). Cell
cycle was analyzed at day 2 using APC BrdU flow Kit (BD
Bioscience). Experiments were performed using FACS Kanto (BD
Bioscience) and analyzed with FlowJo software (Tree Star).
Patient derived xenografts and PDX cultures
PDXs were obtained, maintained, dissociated, and cultured as
described in Garancher et al (2018). PDX3, PDX4, and PDX7 corre-
spond to ICN-MB-PDX-3, ICN-MB-PDX-4, and ICN-MB-PDX-7,
respectively. All in vitro treatments were performed as described for
cell lines.
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Animal experimentation
NMRI-nu immunodeficient mice were obtained from Janvier Labora-
tory. Experiments were performed on 7–8 weeks old female mice
after 1 week of acclimation in animal facility of Curie Institute. Mice
were housed under a controlled temperature and 12 h/12 h light–
dark cycle with access to food and water ad libitum in conventional
animal facility. For the animal welfare, mice are maintained in
social groups with enrichment. Animal care and use for this study
were performed in accordance with the recommendations of the
European Community (2010/63/UE) for the care and use of labora-
tory animals. Experimental procedures were specifically approved
by the ethics committee of the Institut Curie CEEA-IC #118 (Autho-
rization 02383.02 given by National Authority) in compliance with
the international guidelines.
Orthotopic transplantation and pharmacological
inhibitor treatments
NMRI Nude female mice (Janvier labs) were orthotopically
grafted directly in the cerebellum at 7 weeks with 3 × 105 cells/
5 ll of ICN-MB-PDX-4 cells as described in Garancher et al
(2018). After 3 days, mice were administrated 300 ll of
LY2157299 (Galunisertib, AbMole Bioscience) orally at a dose of
75 mg/kg in 12% DMSO, 30% PEG, and water. Mice were treated
7 days a week twice a day until day 30. Mice were injected with
Cisplatin (Sigma) in saline solution at a dose of 2 mg/kg intra-
peritoneally at days 4, 8, and 12 post-grafting. Mice were eutha-
nized when scientific and clinical end points were reached and
brains were collected and fixed.
Tissue processing and immunohistochemistry (IHC)
After 25 days of treatment, 6 mice per group received ice-cold PBS
and 4% formaldehyde/PBS via intracardiac perfusions. Brains were
collected and fixed overnight in 4% formaldehyde/PBS at 4°C. IHC
was performed on 12-lm-thick sections with the following primary
antibodies: anti-PhosphoSmad2 (CST, CS138D4, 1/300), Ki67 (CST,
CS9161, 1/500), and cleaved caspase-3 (eBioscience, #14-5698-82,
1/500). Image acquisitions were performed on a Zeiss microscope.
Tumor size and IHC staining were assessed using ImageJ software.
Quantification and statistical analyses
Western blot was quantified from digital data acquisition (CCD
camera) using ImageJ software. Statistical details can be found in
both figures and figure legends. A P ≤ 0.05 is considered as signifi-
cant. IHC quantifications were assessed using ImageJ software. All
experiments were performed, at least, in three independent tripli-
cates. Statistical analyses are provided in Appendix Table S1
(Statistics related to Figs 1B and 5B and C, and EV1B),
Appendix Table S2 (Statistics related to Figs 1D and 6B, and EV1D
and Appendix Fig S4A), and Appendix Table S3 (Statistics related
to Figs 7D and E, and 6B, and Appendix Fig S3A). The exact
P-values and number of replicates for each experiment are indi-
cated in Appendix Table S5.
Expanded View for this article is available online.
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The paper explained
Problem
Medulloblastoma (MB) is a pediatric tumor of the cerebellum arising
at a median age of 7 years. The current treatment associates surgery,
radiotherapy, and chemotherapy and has allowed reaching an overall
survival of 70–80%. MB is a heterogeneous disease classified in four
groups, with the poorly characterized Group 3 showing the worst
prognosis. Few recurrent genomic alterations have been identified at
low frequency, and at the transcriptional level, Group 3 is known to
express MYC and photoreceptor genes. While highly problematic at
the clinical level, neither specific nor targeted therapy has been iden-
tified for this specific Group.
Results
We show that a subset of Group 3 MBs displays activation of the
TGFb/Activin pathway. In contrast to carcinomas where TGFbs are the
main driver of activation of this pathway, our data established that
this activation is mainly due to an autocrine stimulation involving
ActivinB. We identify a subset of Group 3 tumors in which this mech-
anism is at play. These tumors express high levels of INHBB (encoding
ActivinB) and display high expression of PMEPA1, a well-known target
gene of this signaling pathway. Functionally, the pathway sustains
cell proliferation by inducing the expression of PMEPA1. Importantly,
treatment with Galunisertib, an inhibitor of this pathway currently
tested in clinical trials for Glioblastoma patients, increases the survival
of mice orthotopically grafted with Group 3 MB-PDX.
Impact
TGFb/Activin signaling plays a driving role in a subset of Group 3 MBs.
We propose that high level of Smad2 phosphorylation, high INHBB,
and high expression of PMEPA1 could represent valuable biomarkers
for identifying patients who will be particularly eligible to Galunisertib
treatment.
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For more information
Website team:
(i) https://science.institut-curie.org/research/biology-chemistry-of-radiations-ce
ll-signaling-and-cancer-axis/umr-3347-normal-and-pathological-signaling/
team-eychene-pouponnot/
In situ Hybridization data on the mouse developing brain can be found:
(i) http://developingmouse.brain-map.org/
Public Transcriptomic analysis of MB samples (R2):
(i) https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?&dscope=MB500&option=ab
out_dscope
(ii) https://hgserver1.amc.nl/cgi-bin/r2/main.cgi
Public Proteomic analysis of MB samples:
(i) https://medullo.shinyapps.io/archer2018/
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